Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I ROSSMAN

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Journal of Molecular and Cellular Cardiology|October 13, 2007
Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overloadMichael P Quaile, Eric I Rossman, Remus M Berretta, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|September 30, 2006
Sex-based differences in myocardial contractile reserveRebecca E Petre, Michael P Quaile, Eric I Rossman, et al.
Journal of Molecular and Cellular Cardiology|January 22, 2004
Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardiumEric I Rossman, Rebecca E Petre, Khuram W Chaudhary, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|September 2, 2009
GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogsJames K Hennan, Robert E Swillo, Gwen A Morgan, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2009
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agentsEugene L Piatnitski Chekler, John A Butera, Li Di, et al.
Circulation. Arrhythmia and Electrophysiology|October 8, 2009
Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogsGabriel Laurent, Howard Leong-Poi, Iqwal Mangat, et al.
Journal of the American College of Cardiology|August 18, 2004
Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heartKhuram W Chaudhary, Eric I Rossman, Valentino Piacentino, et al.
Frontiers in Toxicology|November 21, 2025
Rodent home cage monitoring for preclinical safety pharmacology assessment: results of a multi-company validation evaluating nonclinical and clinical data from three compoundsR R Sillito, J Sutherland, A Milne, et al.
Regulatory Toxicology and Pharmacology : RTP|April 15, 2026
Advancing Nonclinical Blood Pressure Assessment: Current Practices and Future Directions in Drug DevelopmentMichael K Pugsley, Siddhartha Bhatt, Christer Gottfridsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2022
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variablesYu Fu, Hadi Taghvafard, Medhat M Said, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Journal of Molecular and Cellular Cardiology|October 13, 2007
Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overloadMichael P Quaile, Eric I Rossman, Remus M Berretta, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|September 30, 2006
Sex-based differences in myocardial contractile reserveRebecca E Petre, Michael P Quaile, Eric I Rossman, et al.
Journal of Molecular and Cellular Cardiology|January 22, 2004
Abnormal frequency-dependent responses represent the pathophysiologic signature of contractile failure in human myocardiumEric I Rossman, Rebecca E Petre, Khuram W Chaudhary, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|September 2, 2009
GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogsJames K Hennan, Robert E Swillo, Gwen A Morgan, et al.
Bioorganic & Medicinal Chemistry Letters|July 21, 2009
Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agentsEugene L Piatnitski Chekler, John A Butera, Li Di, et al.
Circulation. Arrhythmia and Electrophysiology|October 8, 2009
Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogsGabriel Laurent, Howard Leong-Poi, Iqwal Mangat, et al.
Journal of the American College of Cardiology|August 18, 2004
Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heartKhuram W Chaudhary, Eric I Rossman, Valentino Piacentino, et al.
Frontiers in Toxicology|November 21, 2025
Rodent home cage monitoring for preclinical safety pharmacology assessment: results of a multi-company validation evaluating nonclinical and clinical data from three compoundsR R Sillito, J Sutherland, A Milne, et al.
Regulatory Toxicology and Pharmacology : RTP|April 15, 2026
Advancing Nonclinical Blood Pressure Assessment: Current Practices and Future Directions in Drug DevelopmentMichael K Pugsley, Siddhartha Bhatt, Christer Gottfridsson, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 25, 2022
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variablesYu Fu, Hadi Taghvafard, Medhat M Said, et al.
Pageof 5